RATIONALE: The effectiveness of varenicline for smoking cessation has been established, but little is known about the psychological processes that mediate this clinical outcome. OBJECTIVES: This study evaluated the effect of a single dose of varenicline on tonic and cue-provoked changes in craving, withdrawal, and affect using a randomized, double-blind, placebo-controlled, cross-over design. METHODS: Following overnight abstinence, 38 non-treatment-motivated smokers received either varenicline 2mg or matched placebo, then tonic measures of craving, withdrawal, and positive and negative affect were obtained at 30-min intervals. At 4-h post-administration, a cue exposure session obtained the same subjective measures at three time-points following the physical handling of a lit cigarette versus the sharpening and handling of a pencil. RESULTS: At 4-h post-administration, varenicline reduced tonic craving as well as craving across the smoking and neutral cue conditions, relative to placebo. By contrast, the capacity of the smoking cue to enhance craving relative to the neutral cue was unaffected by varenicline. Measures of withdrawal and positive and negative affect produced mixed results. CONCLUSIONS:Acute varenicline selectively attenuates tonic but not cue-provoked craving. This dissociation provides insight into the specific psychological processes that might mediate the effectiveness of varenicline, and highlights cue-provoked craving as a discrete target for advancing smoking cessation pharmacotherapy.
RCT Entities:
RATIONALE: The effectiveness of varenicline for smoking cessation has been established, but little is known about the psychological processes that mediate this clinical outcome. OBJECTIVES: This study evaluated the effect of a single dose of varenicline on tonic and cue-provoked changes in craving, withdrawal, and affect using a randomized, double-blind, placebo-controlled, cross-over design. METHODS: Following overnight abstinence, 38 non-treatment-motivated smokers received either varenicline 2mg or matched placebo, then tonic measures of craving, withdrawal, and positive and negative affect were obtained at 30-min intervals. At 4-h post-administration, a cue exposure session obtained the same subjective measures at three time-points following the physical handling of a lit cigarette versus the sharpening and handling of a pencil. RESULTS: At 4-h post-administration, varenicline reduced tonic craving as well as craving across the smoking and neutral cue conditions, relative to placebo. By contrast, the capacity of the smoking cue to enhance craving relative to the neutral cue was unaffected by varenicline. Measures of withdrawal and positive and negative affect produced mixed results. CONCLUSIONS: Acute varenicline selectively attenuates tonic but not cue-provoked craving. This dissociation provides insight into the specific psychological processes that might mediate the effectiveness of varenicline, and highlights cue-provoked craving as a discrete target for advancing smoking cessation pharmacotherapy.
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Saul Shiffman; Xiaoxue Li; Michael S Dunbar; Hilary A Tindle; Sarah M Scholl; Stuart G Ferguson Journal: Drug Alcohol Depend Date: 2015-07-29 Impact factor: 4.492
Authors: Amanda R Mathew; Jessica L Burris; Brett Froeliger; Michael E Saladin; Matthew J Carpenter Journal: Addict Behav Date: 2015-01-30 Impact factor: 3.913
Authors: Patanjali Ravva; Marc R Gastonguay; Hélène M Faessel; Theodore C Lee; Raymond Niaura Journal: Nicotine Tob Res Date: 2014-08-21 Impact factor: 4.244
Authors: Claire E Wilcox; Vince D Calhoun; Srinivas Rachakonda; Eric D Claus; Rae A Littlewood; Jessica Mickey; Pamela B Arenella; Kent E Hutchison Journal: Psychiatry Res Neuroimaging Date: 2017-04-30 Impact factor: 2.376
Authors: Cynthia A Conklin; Isabella Soreca; David J Kupfer; Yu Cheng; Ronald P Salkeld; Joel M Mumma; John M Jakicic; Christopher J Joyce Journal: Exp Clin Psychopharmacol Date: 2017-07-06 Impact factor: 3.157